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Abstract
Although the rate of new HIV infections has been declining, AIDS continues to be one of the leading causes of
death worldwide. The lack of an effective HIV vaccine makes it necessary to develop alternative strategies, such
as the development of topical microbicides, to prevent transmission. Antimicrobial peptides represent promising
microbicide candidates. Previously, we succeeded in enhancing the anti-HIV activities of several peptides that form
helical structures based on the bioinformatic results learned from the antimicrobial peptide database. This study
showed that Lys-to-Arg alterations also improved the HIV inhibitory activity of thanatin which is known to form a
ȕKDLUSLQ VWUXFWXUH 8VLQJ D SUHYLRXVO\ UHSRUWHG GH QRYR GHVLJQHG +,9 LQKLELWRU\ SHSWLGH */5 DV WKH VWDUWLQJ
WHPSODWHORRSVWUXFWXUHVRIYDU\LQJVL]HVZHUHJHQHUDWHGE\UHVWUDLQLQJDGLVXO¿GHERQGDWGLIIHUHQWSRVLWLRQV7KH
thanatin-mimicking constructs are referred to as GLRC peptides since they are composed of only four amino acid
residues G, L, R, and C. While GLRC-2, the peptide with a medium-sized loop structure, was most potent against
HIV-1 and HSV-2, GLRC-3, with the small loop structure, was most potent against Escherichia coli K12. Thus, the
HI¿FDF\ RI WKH */5& SHSWLGHV LV PLFUREH GHSHQGHQW )XUWKHU WHUPLQDO VHTXHQFH WUXQFDWLRQ RI */5& UHGXFHG
antimicrobial activity against both viruses and bacteria. It appears that the high antiviral potency of GLRC-2 is
related to high hydrophobicity, although a wide-range correlation is lacking. In addition, GLRC-2, which is more
active against viruses, is also more resistant to the action of chymotrypsin. Therefore, GLRC-2, a novel peptide that
DFTXLUHGQRWRQO\KLJKHUVWDELOLW\EXWDOVRKLJKHUDQWL+,9DFWLYLW\WKDQWKH*/5WHPSODWHVHUYHVDVWKHVWDUWLQJ
point for additional rounds of peptide engineering.
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Introduction
Since the report of the first human immunodeficiency virus (HIV)
case in 1981, the acquired immunodeficiency syndrome (AIDS) has
become the fourth leading cause of death worldwide. The United Nations estimates that there are now 40 million people living with HIV/
AIDS. Thus, it is urgent to develop novel therapeutic and preventative
agents to reduce the transmission of HIV. Because the majority of HIV
infections are acquired through heterosexual intercourse, it would be
helpful if measures can be taken to stop or prevent the sexual transmission of HIV [1,2].
We have been focusing on identifying potent anti-HIV candidates
derived from naturally occurring antimicrobial peptides (AMPs). These
peptides have been proven to have antimicrobial effects on a broad
range of bacteria, viruses, fungi, and parasites [3-6]. Select amphibian
and piscine AMPs are known to reduce infectivity of channel catfish
virus (CCV), frog virus 3 (FV3), and HIV [7,8]. In addition, AMPs
with anti-HIV activity have also been discovered from other sources,
which include melittin and cecropin from insects [9], cathelicidins
and defensins from mammals [5,10-13], and cyclotides (i.e. circular
peptides) from plants [14]. We previously identified the most potent as
well as the minimal anti-HIV fragments within human cathelicidin LL37 [13]. A follow-up study showed that LL-37 fragments inhibited HIV
reverse transcriptase in vitro [15]. It is also likely that the antiviral effect
of vitamin D is associated with the expression of human LL-37 in vivo
[16]. We also found that BMAP-18, a fragment derived from bovine
cathelicidin BMAP-27, is a HIV-1 inhibitor (EC50 = 0.83 Pg/ml) with
a therapeutic index (TI) of 24 [13]. To identify additional templates,
we have evaluated 30 peptides selected from the antimicrobial peptide
database [17,18]. The results of that peptide screening led to the
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identification of 10 HIV inhibitory peptides with EC50 values in the
range of 1.0 to 10 Pg/ml [19]. This study extends the results of our
previous studies by evaluating AMPs with different loop structures.
These peptides were designed using GLR-19 as a template. GLR-19
was previously de novo designed based on the antimicrobial peptide
database [17,19]. We also compared the stability of these peptide
scaffolds to the action of chymotrypsin. The results of the current study
are reported herein.

Materials and Methods
Peptides
All the peptides were chemically synthesized using the solid-phase
method and purified by HPLC to >95% (Genemed Synthesis, Inc., TX).

Anti-HIV assays
Anti-HIV-1 cytopathic effect (CPE)-inhibition assays were
performed as described [20]. In brief, serially diluted peptides were
added to a 96-well round bottom microtiter plate in triplicate. CEM-
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SS cells at a concentration of 2.5 u 103 cells per well and HIV-1IIIB
at the appropriate pre-determined titer were sequentially added to
the microtiter plate. The cultures were incubated at 5% CO2/37°C for
six days. Following the incubation, the microtiter plates were stained
with XTT tetrazolium dye to evaluate the efficacy and toxicity of the
test compound(s). Using 4-parameter curve fitting, values of EC50
(50% inhibition of virus replication), and TC50 (50% reduction in
cell viability), as well as a therapeutic index (TI = TC50/EC50), were
determined for each peptide.

Antibacterial assays
The antibacterial activity of the peptides was analyzed using the
standard approach of microdilution [21]. The bacterial strains used
were Escherichia coli K12 and Bacillus subtilis. In brief, small bacterial
cultures were grown overnight. Fresh cultures were inoculated with a
small aliquot of the overnight culture and incubated at 37oC until the
optical density A600 of the culture reached ~0.5. The bacterial culture
(90 Pl each) was then diluted to an A600 of 0.001 and partitioned into a
96-well plate with ~105 colony-forming units (CFU) per well. The cells
were then treated with 10 Pl of the peptide at different concentrations,
allowing the minimum inhibitory concentration (MIC) measurement
for each. The assay was duplicated and repeated multiple times. The
plate was then further incubated at 37oC overnight (~16 hrs) and read
at 630 nm on a ChroMate 4300 microplate reader (GMI, MN).

High performance liquid chromatography (HPLC)
The retention time of the peptide was measured on a Waters HPLC
system equipped with an analytical reverse-phase Waters symmetry
C8 column (150 × 3.9 mm). The peptide was eluted by a gradient of
acetonitrile (containing 1% TFA) from 5% to 95% at a flow rate of 1 ml/
min. The peptide peak was detected by UV at 254 nm.

Electrophoresis assays of peptide stability

activity against HIV-1 but poor activity against HSV-2 (Table 1). To
enhance the anti-HIV activity of SB1, residues K3, K4, and K17 were
converted to arginines based on previous findings from the AMP
database [17,18]. SB2, the arginine analog of SB1, indeed showed
higher activity against HIV-1. However, these changes deprived SB1 of
the weak activity against HSV-2 (Table 1). Since there was no increase
in cytotoxicity, the reduced EC50 value of SB2 directly translated into a
greater TI (Table 1). The TI of SB2 reached 30, which is slightly greater
than those (TI = 21-25) determined for GI-20 (derived from human
LL-37), BMAP-18 (derived from cattle cathelicidin BMAP-27), and an
arginine analog of dermaseptin S9 [13,19].

De novo design of peptides with various loop structures
We designed additional peptides using GLR-19 as the starting
sequence. This peptide is a de novo designed peptide which is known
to be inhibitory to HIV-1 [17,19]. We found that GLR-19 also showed
antiviral activity against HSV-2 (Table 1). To mimic the hairpin
structure of thanatin, we introduced a disulfide bond at different
positions within GLR-19 (Figure 1). In each case, the incorporation
of a disulfide bond into GLR-19 was at the expense of two leucines,
which were replaced by cysteines. Initially, a disulfide bond (yellow
lines in Figure 1) was positioned between residues 2 and 18 (C2-C18)
to generate a large loop structure. This disulfide bond was shifted to
generate additional peptides with a reduced loop size (Figure 1). We
referred to these disulfide bond-linked peptides as GLRC peptides
since their sequences are composed of only G, L, R and C amino acid
residues. GLRC-1, the peptide with the large 17-residue loop, yielded
an EC50 greater than 100 µg/ml, which was the highest concentration
evaluated in antiviral assays [13]. GLRC-2, however, the peptide with
a middle-sized 13-residue loop, demonstrated the highest potency
(EC50 = 1.81 µg/ml). When the size of the loop was furthered reduced
to obtain GLRC-3, antiviral activity was reduced. In parallel antiviral
assays, GLRC-2 also showed the best activity against HSV-2 compared

Peptide (0.5 mM) and chymotrypsin (molar ratio 40:1) were mixed
and incubated at 37oC in 10 mM PBS buffer (pH 8.0). An aliquot
(20 µl) of the reaction was taken at different hours and immediately
mixed with 10 µl of SDS loading buffer to terminate the action of the
protease. Aliquots of the reactions were subsequently analyzed using
18% stacking tricine SDS-PAGE. The bands were stained by Coomassie
Brilliant Blue R250 (Fisher). Images of the gels were taken and digitized
in Photoshop 6.0 for band quantification.

Results
Engineering of HIV inhibitory peptides based on an AMP
with a b-sheet structure
Our previous studies focused on linear peptides from which several
HIV inhibitory candidates have been identified. Those peptides such
as the GI-20 and BMAP-18 have a tendency to form amphipathic
helical structures, especially when in complex with membranes [2123]. In this study, BAMP-18 was included as a control and it showed
a similar efficacy in Table 1 as reported previously [13]. To expand
the conformation space, we shifted our focus to AMPs with a P-sheet
structure. Thanatin is a natural AMP isolated from the insect Podisus
maculiventris (i.e., the spined soldier bug) [24]. This peptide was
chosen because it has a simple hairpin structure with a single disulfide
bond (C11-C18) between the two strands (Figure 1A) [25]. Two
derivatives of thanatin were obtained. In the structure-based peptide
1 (SB1), the last residue Met of thanatin was substituted with Ile to
reduce possible oxidation of the peptide. This peptide demonstrated

J AIDS Clinic Res

Figure 1: De novo design of novel anti-HIV peptides by mimicking the E-hairpin
structure of thanatin. (A) A ribbon view of the 3D structure of thanatin (PDB
,'7)9 >@7KHGLVXO¿GHERQGLVUHSUHVHQWHGE\DSDLURI\HOORZEDOOV % 
Systematic construction of peptides with varying loops or scaffolds. The starting
WHPSODWH*/5FRQVLVWVRIRQO\WKUHHIUHTXHQWO\RFFXUULQJUHVLGXHVIRXQGLQ
natural antimicrobial peptides collected in the antimicrobial peptide database
[17, 19]. For additional details on peptide design, see the text. Yellow bars repUHVHQWDGLVXO¿GHERQGDQGWKHSHSWLGHFKDLQLQRUDQJH7KHDQWL+,9DFWLYLW\
for each peptide fold (i.e. the EC50 value from Table 1) is given in parenthesis.
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Peptide

# of
AA

Amino acid
VHTXHQFH

HIV-1IIIB in CEM-SS cells
S-S bond

HSV-2MS in Vero cells

EC50a
(Pg/ml)

TC50
(Pg/ml)

TI

EC50
(Pg/ml)

TC50
(Pg/ml)

TI

0.83

19.8

23.9

27.2

>100

>3.7

BMAP-18

GRFKRFRKK
FKKLFKKIS

18

SB1

GSKKPVPIIYC
NRRTGKCQRI

21

C11-C18

13.1

>100

>7.6

64.9

>100

>1.5

SB2

GSRRPVPIIYC
NRRTGRCQRI

21

C11-C18

3.33

>100

>30

>100

>100

---

GLK-19

GLKKLLGKLL
KKLGKLLLK

19

>47.5

25.1

<0.5

n.e.b

n.e.

GLR-19

GLRRLLGRLL
RRLGRLLLR

19

4.06

17.8

4.4

2.32

12.4

5.3
>3.3

GLRC-1

GCRRLLGRLLRRLGRLLCR

19

C2-C18

>100

59.2

<1.0

30

>100

GLRC-2

GLRCRLGRLLRRLGRCLLR

19

C4-C16

1.81

17.8

9.83

5.43

31.8

5.9

GLRC-3

GLRRLCGRLGRRLCRLLLR

19

C6-C14

6.37

18.5

2.9

15

62.3

4.2

GLRC-4

GCRRLCGRLGRRLCRLLCR 19

C2-C18
C6-C14

69.3

>100

>1.44

64.7

>100

>1.5

GLRC-5

GLRCRLGRLLRRLGRC

16

C4-C16

>100

59.5

<1.00

n.e.

n.e.

GLRC-6

CRLGRLLRRLGRCLLR

16

C1-C13

7.72

41.9

5.43

n.e.

n.e.

GLRC-7

CRLGRLLRRLGRC

13

C1-C13

>100

>100

---

n.e.

n.e.

GLRC-8

GLRCLRLRGRLRLGRCLLR

19

C4-C16

>100

31

<1.00

n.e.

n.e.

Table 1: Antiviral activities of de novo designed peptides. aAlthough not provided in the table, the standard error from multiple antiviral assays is on average less than
10% of the respective mean EC50 or TC50 values. bn.e., not evaluated.
Peptide
name

Net
charge

# of
R or K

Pho%

HPLC
tR (min)

Boman
index

E. coli
MIC (PM)
a

B. subtilis
MIC (PM)

GLK-19

7

7K

47

9.776

-0.43

10

n.e.b

GLR-19

7

7R

47

9.263

3.01

>120

n.e.

GLRC-1

7

7R

47

7.452

3.4

30

>120

GLRC-2

7

7R

47

12.344

3.4

30

>120

GLRC-3

7

7R

47

10.101

3.4

7.5

>120

GLRC-4

7

7R

47

9.601

3.78

60

>120

GLRC-5

7

6R

43

9.373

3.39

60

>120

GLRC-6

7

6R

50

9.395

3.47

30

60

GLRC-7

6

5R

46

8.734

3.88

120

>120

GLRC-8

8

7R

47

9.18

3.4

15-30

>120

Table 2: Effects of peptide scaffolds on their bacterial inhibitory activities. a. Data were taken from ref. [19]. bn.e., not evaluated.

to both GLRC-1 and GLRC-3 (Table 1). These results highlight the
importance of the C4-C16 disulfide linkage in GLRC-2. Consistent
with this observation, GLRC-4 was also determined to be inactive when
two different disulfide bonds (C2-C18 and C6-C14) were applied in
the peptide. However, the GLRC peptides with disulfide bonds all had
reduced activity against HSV-2 compared to the linear template GLR19 (Table 1). The possibility that linear AMPs are generally more active
than their disulfide counterparts against HSV-2 remains to be tested.
Next, we further mimicked the scaffold of SB2 by removing either
the N- or the C-terminal residues outside of the loop (Figure 1). When
the C-terminal segment LLR was truncated, the resulting peptide
GLRC-5 became inactive. In contrast, the peptide GLRC-6 remained
active after the N-terminally exposed residues, GLR, of GLRC-2 were
removed. Another peptide (GLRC-7) was obtained by removing
both the N- and C-terminal segments outside of the loop of GLRC2. Like GLRC-5, GLRC-7 was inactive. These results suggest that the
C-terminal LLR segment of GLRC-2 is important for anti-HIV activity.
We also evaluated if the sequence of the central fragment between the
two Cys residues of GLRC-2 played a role in antiviral activity. To
address this question, we altered the sequence order without changing
the amino acid composition. To our surprise, the resulting peptide
GLRC-8 was found to be inactive (Table 2). We conclude that both the

J AIDS Clinic Res

order of the central sequence and the C-terminal region of GLRC-2
play an important role in HIV inhibition.
Because these GLRC peptides are novel, we also evaluated their
antibacterial activity using representative laboratory strains. Overall,
these peptides showed poor activity against Gram-positive B. subtilis
(Table 2). In the case of Gram-negative E. coli K12, the most active
peptide (MIC = 7.5 µM) was GLRC-3, the peptide with the smallest
loop (Figure 1). Peptides GLRC-1, GLRC-2, GLRC-6, and GLRC-8
showed similar anti-E. coli activity (MIC = 30 µM), indicating that the
N-terminal segment GLR of GLRC-2 is dispensable for antibacterial
activity. Interestingly, the least active peptide was determined to be
GLRC-7, the shortest GLRC peptide with a 13-residue loop structure.
Thus, the C-terminal segment of GLRC-2 appears to be important also
for bactericidal activity.

Peptide parameters that influence activity
To provide further insight into the antimicrobial activities of these
peptide constructs, we measured the retention times of the GLRC
peptides by reverse-phase HPLC (Table 2). The retention time is
related to peptide hydrophobicity [23]. Other parameters such as net
charge, hydrophobic residues% (pho% in Table 3), and Boman index
[18] (i.e. protein binding potential) [3] were also calculated for the

Pharmacology of Antiretroviral Agents: HIV

ISSN:2155-6113 JAR, an open access journal

Citation: Wang G, Buckheit KW, Mishra B, Lushnikova T, Buckheit RW (2011) De Novo Design of Antiviral and Antibacterial Peptides with Varying Loop
Structures. J AIDS Clinic Res S2:003. doi:10.4172/2155-6113.S2-003

Page 4 of 5
GRLC peptides using the prediction interface of the AMP database
(http://aps.unmc.edu/AP/main.html) [18] and are included in Table
3. While it is not obvious why GRLC-3 is most active against E. coli,
the high potency of GLRC-2 against HIV-1 is likely to be due to high
hydrophobicity of the peptide, which has the longest retention time
(tR) (Table 2).

enhancement [26]. After activity enhancement, several anti-HIV
peptides in the helical family were obtained with TIs >20. The current
study identified a β-hairpin peptide SB2 with a TI = 30 by using the
same Lys-to-Arg mutational strategy [19]. It seemed that this strategy
might be applicable to the improvement of anti-HIV activity of AMPs
with different structural scaffolds.

Stability of the GLRC peptides to chymotrypsin

The establishment of the antimicrobial peptide database facilitated
bioinformatic analysis of natural AMPs from a defined family or
source [17,18]. For example, the frequently occurring residues from
amphibian AMPs were identified as G, L, A, and K. The peptide, GLK19 (Table 1), was previously de novo designed using only G, L, and
K residues. GLK-19 was found to be active against Gram-negative E.
coli but not Gram-positive Staphylococcus aureus [17]. Because only
AMPs with antiviral activity are known to have an R/K ratio greater
than one in our database, GLR-19 was designed by converting all
lysines to arginines. While GLK-19 showed no HIV-1 inhibitory
activity at a peptide concentration of 100 Pg/ml, GLR-19 was found to
be active against both HIV-1 [19] and HSV-2 (Table 1). In this study,
we have designed a series of peptides with loop structures based on
the linear peptide GLR-19 (Figure 1). We demonstrated that the antiHIV activity of the peptide was also dependent on the loop size. While
GLRC-2 with a medium 13-residue loop was the most potent against
HIV-1, GLRC-3 with a small 9-residue loop was the most active against
E. coli. It is evident that the optimal design of an antimicrobial peptide
is microbe dependent.

We also compared the stability of the GLRC peptides to
the action of proteases such as chymotrypsin. Figure 2 shows the
percentage of intact peptide after protease treatment at 37oC for 4
hrs. For comparison, SB1 was also tested and was found to have 23%
intact peptide remaining at 4 hrs. Compared to SB1, the linear template
GLR-19, with 15.5% intact peptide remaining, was less stable (Figure
2). Restraining the GLR-19 polypeptide chain with disulfide bonds
had a significant impact on peptide stability. First, we determined that
peptide stability was related to the loop size: GLRC-2 > GLRC-1 >
GLRC-3 (Figure 1). Thus, GLRC-2, with a medium-sized loop structure,
acquired improved stability (>60% intact peptide) compared to SB1
(23% intact peptide, Figure 2). The stability of GLRC-2 increased by
4.4 fold relative to GLR-19. Note that GLRC-4, with two disulfide bond
patterns as in GLRC-1 (C2-C18) and GLRC-3 (C6-C14), did not gain
additional stability to the protease, further indicating the importance
of the C4-C16 disulfide bond. Second, although GLRC-2 and GLRC-8
share the medium-sized loop, they had drastically different stability. It
is likely that the sequence order in the loop determines the extent of
overall packing of the peptide chain. Third, the segment outside of the
loop appeared to be critical for GLRC-2 stability. In particular, removal
of the N-terminal segment was detrimental, leading to complete
degradation of the peptide in four hours. The C-terminal segment was
less important with about 50% of the peptide remaining at 4 hrs. This
is in contrast to the importance of the C-terminal segment for antiHIV activity. Nevertheless, it is interesting to note that GLRC-2, which
demonstrated the greatest activity against HIV-1 (Table 1), was also the
most stable to protease compared to the other GLRC peptides (Figure
2).

Discussion
In order to identify AMP candidates as lead products for the
development of topical microbicides, we have continued our efforts to
search for potent anti-HIV peptides. In our previous studies [13,19],
different engineering strategies were adopted. These included database
screening, sequence shuffling, and database-aided antiviral activity

Figure 2: Stability comparison of the de novo designed GLRC peptides after
incubation with chymotrypsin at 37oC for 4 hrs (see Methods). Both SB1 and
GLR-19 are included for comparison. The percentages of uncleaved peptides
are represented by the height of the bars and also indicated at the top of the
bars. For example, GLRC-5 had ~50% intact peptide remaining after 4 hrs.

J AIDS Clinic Res

Because these de novo designed peptides have a relatively simple
amino acid composition, we also investigated possible structureactivity correlations. In the case of E. coli, there was no clear
correlation between peptide activity and any physical parameters
listed in Table 2, including net charge, the number of Lys or Arg,
percentage of hydrophobic residues, Boman index [18] (or protein
binding potential [3], and HPLC retention time (hydrophobicity). For
the GLRC peptides, however, we noticed that GLRC-7, with a minimal
number of positively charged residues, was the least active against
Gram-negative E. coli, whereas GLRC-6, with the highest hydrophobic
content (50%), is the only peptide that was moderately active against
Gram-positive B. subtilis (Table 2). These observations are in line with
the current knowledge on AMPs in general [26]. It was also difficult
to find any correlation between anti-HIV activity and these peptide
properties. These observations indicate that multiple factors determine
the biological activity of these AMPs. However, for the three most
active GLRC peptides, their HIV inhibitory activities were found to
be proportional to hydrophobicity as measured by HPLC (Tables 1
& 2). In particular, the higher activity of GLRC-2 corresponded with
its higher hydrophobicity, although this correlation could not be
extended to all the peptides in Table 1. Craik and colleagues noticed
that, among the HIV inhibitory plant cyclotides, cycloviolacin Y5,
isolated from the traditional Chinese herb Viola yedoensis, was the
most hydrophobic and also the most potent [27]. They proposed that
cycloviolacin Y5 acted on viral membranes. Whether GLRC-2 acts by
the same mechanism remains to be established. Interestingly, GLRC-2
also showed higher stability to the action of chymotrypsin compared to
the other members of the GLRC peptide family as well as to its linear
template GLR-19 (Figure 2).
In summary, we have demonstrated the enhancement of anti-HIV
activity of linear AMPs that tend to form amphipathic helical structures
using the Lys-to-Arg mutational strategy [19]. We illustrated here that
anti-HIV activity of SB1, a thanatin analog with a E-hairpin fold, could
also be improved by the same strategy [19]. Our current study has
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expanded our knowledge of the relationship between AMP structure
and anti-HIV activity. In addition to peptide length, sequence order,
charge, amino acid type, and structure [13,19], peptide scaffolds or
folds also play a pivotal role (Tables 1 & 2). Evaluation of peptides with
varying scaffolds is important because of their different susceptibilities
to proteases (Figure 2). This study led to the discovery of a novel
peptide GLRC-2 that demonstrated both greater anti-HIV activity
and greater stability to chymotrypsin over the GLR-19 template. These
results should be helpful for our future design of highly potent antiHIV peptides with desired stability. In addition, our studies may also
contribute to the identification of novel antimicrobial agents with
activity against other viral and bacterial pathogens.
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